Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/170588
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sánchez, Aroha B. | - |
dc.contributor.author | Calpena Campmany, Ana Cristina | - |
dc.contributor.author | Soriano-Ruiz, José L. | - |
dc.contributor.author | Gálvez Martín, Patricia | - |
dc.contributor.author | Clares Naveros, Beatriz | - |
dc.date.accessioned | 2020-09-14T09:30:34Z | - |
dc.date.available | 2021-06-09T05:10:21Z | - |
dc.date.issued | 2020-06-09 | - |
dc.identifier.issn | 1743-5889 | - |
dc.identifier.uri | http://hdl.handle.net/2445/170588 | - |
dc.description.abstract | Anti-inflammatory drugs Anti-inflammatory drugs constitute the backbone of treatment for most diseases. In fact, there is a direct relationship between chronic inflammation and many emerging disorders like cancer, oral diseases, kidney diseases, fibromyalgia, GI chronic diseases or rheumatic diseases [1]. Steroidal anti-inflammatory drugs (SAIDs) and nonsteroidal antiinflammatory drugs (NSAIDs) are key contributors in the treatment of acute inflammatory pain conditions such as headache, postoperative pain and orthopedic fractures as well as in the management of chronic inflammatory pain and inflammatory diseases like rheumatoid arthritis, osteoarthritis and gout and for ocular diseases [2]. The principal therapeutic applications of NSAIDs are related to pain, fever and they can also be used as a prophylaxis treatment after first coronary or cerebrovascular ischemic event, this is one of the most important usages of acetylsalicylic acid (ASA) [3]. Principal therapeutic areas for SAIDs are allergic rhinitis (nasally administered) [4], asthma [5], nasal polyposis and chronic rhinosinusitis [6,7].Orally administered prednisolone, a SAID, is indicated in bronchial asthma, allergic and inflammatory disorders, rheumatoid arthritis and other collagenopathies, dermatitis and dermatoses such as subacute and chronic eczema, psoriasis and pemphigus. | - |
dc.format.extent | 4 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Future Medicine | - |
dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.2217/nnm-2020-0064 | - |
dc.relation.ispartof | Nanomedicine, 2020, vol. 15, num. 14, p. 1357-1360 | - |
dc.relation.uri | https://doi.org/10.2217/nnm-2020-0064 | - |
dc.rights | (c) Future Medicine, 2020 | - |
dc.source | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) | - |
dc.subject.classification | Agents antiinflamatoris | - |
dc.subject.classification | Administració de medicaments | - |
dc.subject.classification | Nanomedicina | - |
dc.subject.other | Antiinflammatory agents | - |
dc.subject.other | Administration of drugs | - |
dc.subject.other | Nanomedicine | - |
dc.title | Anti-inflammatory nanomedicines: what does the future hold? | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 702981 | - |
dc.date.updated | 2020-09-14T09:30:35Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
702981.pdf | 1.25 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.